COR Stock Analysis: Cencora | NYSE
Medical Distribution | NYSE, USA | Market Cap: 63.154m USD | 12M Return: 9.1% | US03073E1055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 384M
EPS Trend: 99.7%
Qual. Beats: 1
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cencora, Inc. (NYSE: COR) is a large-cap U.S. pharmaceutical distributor operating through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The company sources and distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies, plasma and blood products, vaccines, specialty drugs, and animal health products. Its customer base spans acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, long-term care facilities, and veterinary markets.
Beyond physical distribution, Cencora offers a broad services portfolio, including pharmacy management and consulting, supply management software, packaging solutions, clinical trial and commercialization support, data analytics, sales force services for manufacturers, and specialty transportation and logistics for the biopharmaceutical industry. The company was founded in 1871, is headquartered in Conshohocken, Pennsylvania, and was renamed from AmerisourceBergen Corporation to Cencora, Inc. in August 2023.
As a member of the U.S. drug wholesaling Big 3 alongside McKesson and Cardinal Health, Cencora operates in a high-volume, low-margin industry that serves as a critical link between pharmaceutical manufacturers and a fragmented base of healthcare providers, giving it significant scale advantages in purchasing and logistics.
- GLP-1 drug volumes accelerate U.S. pharmaceutical distribution growth
- Opioid litigation settlements pressure near-term operating margins
- Specialty pharma services revenue scales double digits globally
| Net Income: 2.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.30 > 1.0 |
| NWC/Revenue: -1.16% < 20% (prev -1.62%; Δ 0.46% < -1%) |
| CFO/TA 0.06 > 3% & CFO 4.82b > Net Income 2.62b |
| Net Debt (8.91b) to EBITDA (5.13b): 1.74 < 3 |
| Current Ratio: 0.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.9m) vs 12m ago -0.66% < -2% |
| Gross Margin: 3.71% > 18% (prev 3.06%; Δ 0.65% > 0.5%) |
| Asset Turnover: 421.9% > 50% (prev 428.2%; Δ -6.30% > 0%) |
| Interest Coverage Ratio: 8.20 > 6 (EBIT TTM 4.08b / Interest Expense TTM 497.8m) |
| A: -0.05 (Total Current Assets 55.3b - Total Current Liabilities 59.2b) / Total Assets 83.8b |
| B: 0.11 (Retained Earnings 9.14b / Total Assets 83.8b) |
| C: 0.05 (EBIT TTM 4.08b / Avg Total Assets 78.9b) |
| D: 0.04 (Book Value of Equity 3.05b / Total Liabilities 80.6b) |
| Altman-Z'' = 0.44 = B |
| DSRI: 0.99 (Receivables 25.4b/24.6b, Revenue 333b/317b) |
| GMI: 0.83 (GM 3.06% / 3.71%) |
| AQI: 1.00 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 1.05 (Revenue 333b / 317b) |
| TATA: -0.03 (NI 2.62b - CFO 4.82b) / TA 83.8b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of September 11, 2026, the stock is trading at USD 320.95 with a total of 1,161,539 shares traded. Over the past week, the price has changed by -4.58%, over one month by -1.05%, over three months by +14.34% and over the past year by +9.14%.
Current recommended Stop Loss: 308.20 (which is 4% or 1.7 ATR below the current price).
Cencora has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy COR.
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 369.3 | 15.1% |
P/E Trailing = 25.072
P/E Forward = 16.8919
P/S = 0.1898
P/B = 21.0382
P/EG = 0.7043
Revenue TTM = 333b USD
EBIT TTM = 4.08b USD
EBITDA TTM = 5.13b USD
Long Term Debt = 11.4b USD (from longTermDebt, last quarter)
Short Term Debt = 279.2m USD (from shortTermDebt, last quarter)
Debt = 11.7b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.91b USD (calculated: Debt 11.7b - CCE 2.82b)
Enterprise Value = 72.1b USD (63.2b + Debt 11.7b - CCE 2.82b)
Interest Coverage Ratio = 8.20 (Ebit TTM 4.08b / Interest Expense TTM 497.8m)
EV/FCF = 17.75x (Enterprise Value 72.1b / FCF TTM 4.06b)
FCF Yield = 5.63% (FCF TTM 4.06b / Enterprise Value 72.1b)
FCF Margin = 1.22% (FCF TTM 4.06b / Revenue TTM 333b)
Net Margin = 0.79% (Net Income TTM 2.62b / Revenue TTM 333b)
Gross Margin = 3.71% ((Revenue TTM 333b - Cost of Revenue TTM 320b) / Revenue TTM)
Gross Margin QoQ = 4.26% (prev 4.24%)
Tobins Q-Ratio = 0.86 (Enterprise Value 72.1b / Total Assets 83.8b)
Interest Expense / Debt = 4.25% (Interest Expense 497.8m / Debt 11.7b)
Taxrate = 26.82% (967.3m / 3.61b)
NOPAT = 2.99b (EBIT 4.08b * (1 - 26.82%))
Current Ratio = 0.93 (Total Current Assets 55.3b / Total Current Liabilities 59.2b)
Debt / Equity = 3.84 (Debt 11.7b / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = 1.74 (Net Debt 8.91b / EBITDA 5.13b)
Debt / FCF = 2.19 (Net Debt 8.91b / FCF TTM 4.06b)
Total Stockholder Equity = 2.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.33% (Net Income 2.62b / Total Assets 83.8b)
RoE = 106.4% (Net Income TTM 2.62b / Total Stockholder Equity 2.47b)
RoCE = 29.36% (EBIT 4.08b / Capital Employed (Equity 2.47b + L.T.Debt 11.4b))
RoIC = 13.54% (NOPAT 2.99b / Invested Capital 22.1b)
WACC = 4.58% (E(63.2b)/V(74.9b) * Re(4.85%) + D(11.7b)/V(74.9b) * Rd(4.25%) * (1-Tc(0.27)))
Discount Rate = 4.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.10 | Cagr: -1.61%
[DCF] Terminal Value 77.97% ; FCFF base≈2.89b ; Y1≈3.32b ; Y5≈4.88b
[DCF] Fair Price = 338.2 (EV 73.4b - Net Debt 8.91b = Equity 64.5b / Shares 190.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.69 | EPS CAGR: 14.19% | SUE: 1.10 | # QB: 1
Revenue Correlation: 98.53 | Revenue CAGR: 9.29% | SUE: 0.36 | # QB: 0
EPS current Quarter (2026-12-31): EPS=4.61 | Chg30d=+2.21% | Revisions=+0% | Analysts=7
EPS current Year (2026-09-30): EPS=17.87 | Chg30d=+0.51% | Revisions=+77% | GrowthEPS=+11.7% | GrowthRev=+4.9%
EPS next Year (2027-09-30): EPS=19.80 | Chg30d=-0.01% | Revisions=-18% | GrowthEPS=+10.8% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +32% (up=15, down=7)